Neuroscience

Targeting tau, the other protein behind Alzheimer's disease

In November, researchers reported the drug lecanemab slowed the progression of Alzheimer's disease. The effect was modest, but it has generated tremendous excitement because it was the first time a drug had been shown to ...

Alzheimer's disease & dementia

Japan approves Alzheimer's blood test kit

Japan has approved a blood test kit to diagnose Alzheimer's disease, its manufacturer announced on Thursday, a rare advance in tackling a condition that affects tens of millions worldwide.

page 1 from 32

Beta amyloid

Amyloid beta (Aβ or Abeta) is a peptide of 39–43 amino acids that appear to be the main constituent of amyloid plaques in the brains of Alzheimer's disease patients. Similar plaques appear in some variants of Lewy body dementia and in inclusion body myositis, a muscle disease. Aβ also forms aggregates coating cerebral blood vessels in cerebral amyloid angiopathy. These plaques are composed of a tangle of regularly ordered fibrillar aggregates called amyloid fibers, a protein fold shared by other peptides such as prions associated with protein misfolding diseases. Research on laboratory rats suggest that the two-molecule, soluble form of the peptide is a causative agent in the development of Alzheimer's and that the two-molecule form is the smallest synaptotoxic species of soluble amyloid beta oligomer

This text uses material from Wikipedia, licensed under CC BY-SA